Related Experiment Video
Updated: Oct 13, 2026

Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Plasma and platelet plasminogen activator inhibitor-1 in patients with acute myocardial infarction
1Department of Cardiology and Clinical Research Institute, Zentsuji National Hospital, Zentsuji City, Kagawa, Japan. tsoeki@jun.ncvc.go.jp
Insights
Platelet plasminogen activator inhibitor-1 (PAI-1) levels increase during acute myocardial infarction (AMI), suggesting platelet PAI-1 release contributes to thrombus formation in coronary artery disease (CAD).
Area of Science:
- Cardiovascular Medicine
- Hematology
- Thrombosis and Hemostasis
Background:
- Elevated plasma plasminogen activator inhibitor-1 (PAI-1) is linked to coronary artery disease (CAD).
- Platelet PAI-1, comprising over 90% of blood PAI-1, remains unquantified in CAD patients.
- Understanding platelet PAI-1 dynamics is crucial for CAD and acute myocardial infarction (AMI) research.
Purpose of the Study:
- To investigate plasma and platelet PAI-1 concentrations in CAD patients.
- To analyze serial changes in PAI-1 and fibrinolytic factors during AMI.
- To explore the relationship between plasma and platelet PAI-1 in CAD and AMI.
Main Methods:
- Coronary angiography was performed on 72 subjects categorized into non-CAD, CAD, and AMI groups.
- Plasma and platelet concentrations of PAI-1, tissue plasminogen activator (t-PA), and related factors were measured.
- Serial measurements were conducted in the AMI group post-percutaneous transluminal coronary angioplasty.
Main Results:
- Plasma PAI-1, t-PA, and t-PA x PAI-1 complex were elevated in AMI patients on day 1 compared to CAD groups.
- Platelet PAI-1 concentrations were significantly higher in the AMI group on day 1.
- Platelet PAI-1 levels decreased serially in AMI patients, correlating positively with plasma PAI-1 in the overall cohort.
Conclusions:
- Platelet PAI-1 accumulation and subsequent release into plasma may drive thrombus formation during AMI.
- Platelet PAI-1 serves as a potential biomarker and therapeutic target in acute myocardial infarction.
- This study highlights the critical role of platelet-derived PAI-1 in the pathophysiology of CAD and AMI.
Abstract:
Several studies have demonstrated an increased level of plasma plasminogen activator inhibitor-1 (PAI-1) in patients with coronary artery disease (CAD). However, the concentration of PAI-1 in platelets, which accounts for more than 90% of the blood PAI-1, is unknown in these patients. The present study evaluated the concentrations of PAI-1 and several fibrinolytic factors in the plasma and platelets of patients with CAD and the serial changes in patients with acute myocardial infarction (AMI). All 72 subjects had coronary angiography and were divided into 3 groups: CAD(-) group without coronary artery stenosis or myocardial ischemia (n=20), CAD(+) group with either stable angina pectoris (n=18) or old myocardial infarction (n=12) with coronary artery stenosis, and the AMI group admitted within 24h of symptom onset who underwent successful percutaneous transluminal coronary angioplasty (n=22). The concentrations of plasma PAI-1, tissue plasminogen activator (t-PA), and t-PA x PAI-1 complex were similar in the CAD(-) and CAD(+) groups, but were greater on day 1 in the AMI group compared with the 2 CAD groups. There were no significant differences between the 3 groups in the plasma concentrations of thrombin antithrombin III complex (TAT), alpha2-plasmin inhibitor-plasmin complex (PIC), beta-thromboglobulin (beta-TG), and platelet factor 4 (PF-4). The platelet PAI-1 concentrations did not differ between the CAD(-) and CAD(+) groups, but was greater on day 1 in the AMI group compared to the CAD groups. The platelet beta-TG and PF-4 were similar between the 3 groups. In the AMI group, both the plasma and platelet PAI-1 concentrations were greater on day 1, but the plasma PAI-1 rapidly decreased by day 5 and remained low on day 28 compared with day 1. The platelet PAI-1 concentration gradually decreased by day 5 and was further decreased by day 28. The serial changes of the plasma t-PA and t-PA PAI-1 complex during the course of AMI were similar to those of the plasma PAI-1. A positive correlation was found between the plasma and platelet PAI-1 in all 72 patients, but not in the AMI group alone. These results suggest that the PAI-1 that has accumulated in platelets at the onset of AMI might be released in large amounts into the plasma, resulting in an increase in thrombus formation.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Clot Retraction and Fibrinolysis
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Acute Coronary Syndrome IV: Interprofessional Care
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

